The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...

The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Avoid excessive force when inserting ...

Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging efforts Positions Organon for future investment in growth opportunities with a focus on women’s health ...

“ Given the results of the PEARLE Study, the Jada System offers an important new tool as we continue to strive to decrease rates of severe maternal morbidity and mortality from hemorrhage in the ...

Organon, a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of ...

Please provide your email address to receive an email when new articles are posted on . The JADA system decreased abnormal postpartum uterine bleeding in vaginal and cesarean birth, regardless of ...

Please provide your email address to receive an email when new articles are posted on . Treatment success for the JADA system was high for both vaginal and cesarean births. Overall, 2.8% of women in ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...

Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered ...